Monoamine transporters Structure, regulation, and clinical implications

Neurology

Volumn 81, Issue 8, 2013, Pages 761-768

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMFEBUTAMONE; AMITRIPTYLINE; ATOMOXETINE; CARRIER PROTEINS AND BINDING PROTEINS; CITALOPRAM; COAT PROTEIN COMPLEX II; COCAINE; DOPAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; NOMIFENSINE; NORADRENALIN; PAROXETINE; PLASMA MEMBRANE MONOAMINE TRANSPORTER; PROTEIN KINASE C; REBOXETINE; RESERPINE; SEROTONIN; SERTRALINE; TETRABENAZINE; UNCLASSIFIED DRUG; VENLAFAXINE; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BINDING SITE; CELL MEMBRANE; CELL TRANSPORT; DEPRESSION; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; IN VITRO STUDY; INTESTINE INNERVATION; INTRACELLULAR SPACE; LOCOMOTION; LOSS OF FUNCTION MUTATION; MEMBRANE STRUCTURE; MONOAMINE NERVE CELL; MONOAMINE RELEASE; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE ENDING; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PATHOPHYSIOLOGY; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; SECRETORY PATHWAY; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPSE VESICLE; SYNAPTOSOME; TARDIVE DYSKINESIA;

ANIMALS; CELL MEMBRANE; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MODELS, NEUROLOGICAL; SYNAPSES; SYNAPTIC TRANSMISSION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84884472006     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a1ab4a     Document Type: Article

References (60)

1. Gether U, Andersen PH, Larsson OM, Schousboe A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 2006;27: 375-383.
2. Kristensen AS, Andersen J, Jorgensen TN, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 2011;63:585-640.
3. Sager JJ, Torres GE. Proteins interacting with monoamine transporters: current state and future challenges. Biochemistry 2011;50:7295-7310.
4. Lin Z, Canales JJ, Bjorgvinsson T, et al. Monoamine transporters: vulnerable and vital doorkeepers. Prog Mol Biol Transl Sci 2011;98:1-46.
5. Wimalasena K. Vesicular monoamine transporters: structurefunction, pharmacology, and medicinal chemistry. Med Res Rev 2011;31:483-519.
6. Hahn MK, Blakely RD. The functional impact of SLC6 transporter genetic variation. Annu Rev Pharmacol Toxicol 2007;47:401-441.
7. Chen NH, Reith ME, Quick MW. Synaptic uptake and beyond: the sodium-and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch 2004; 447:519-531.
8. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na1/Cl-dependent neurotransmitter transporters. Nature 2005;437: 215-223.
9. Zhao Y, Terry DS, Shi L, et al. Substrate-modulated gating dynamics in a Na1-coupled neurotransmitter transporter homologue. Nature 2011;474:109-113.
10. Oaks AW, Sidhu A. Synuclein modulation of monoamine transporters. FEBS Lett 2011;585:1001-1006.
11. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010;329:1537-1541.
12. Zhuang X, Oosting RS, Jones SR, et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 2001;98:1982-1987.
13. Viggiano D, Ruocco LA, Sadile AG. Dopamine phenotype and behaviour in animal models: in relation to attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2003;27:623-637.
14. Fan X, Bruno KJ, Hess EJ. Rodent models of ADHD. Curr Top Behav Neurosci 2012;9:273-300.
15. Thomsen M, Han DD, Gu HH, Caine SB. Lack of cocaine self-administration in mice expressing a cocaineinsensitive dopamine transporter. J Pharmacol Exp Ther 2009;331:204-211.
16. Xu F, Gainetdinov RR, Wetsel WC, et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 2000;3:465-471.
17. Kaminski RM, Shippenberg TS, Witkin JM, Rocha BA. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neurosci Lett 2005;382:51-55.
18. Bohn LM, Xu F, Gainetdinov RR, Caron MG. Potentiated opioid analgesia in norepinephrine transporter knockout mice. J Neurosci 2000;20:9040-9045.
19. Solich J, Faron-Gorecka A, Kusmider M, Palach P, Gaska M, Dziedzicka-WasylewskaM. Norepinephrine transporter (NET) knock-out upregulates dopamine and serotonin transporters in the mouse brain. Neurochem Int 2011;59:185-191.
20. Kalueff AV, Jensen CL, Murphy DL. Locomotory patterns, spatiotemporal organization of exploration and spatial memory in serotonin transporter knockout mice. Brain Res 2007;1169:87-97.
21. Jennings KA, Loder MK, Sheward WJ, et al. Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci 2006;26:8955-8964.
22. Henry JP, Botton D, Sagne C, et al. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J Exp Biol 1994;196:251-262.
23. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH. Differential expression of two vesicular monoamine transporters. J Neurosci 1995;15:6179-6188.
24. Multani PK, Hodge R, Estevez MA, et al. VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination. Neuroscience 2012;232C:32-44.
25. Ashe KM, Chiu WL, Khalifa AM, et al. Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain. Neuro Endocrinol Lett 2011; 32:253-258.
26. Lohoff FW. Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders. Methods Mol Biol 2010;637:165-180.
27. Theodore S, Cass WA, Dwoskin LP, Maragos WF. HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum. Synapse 2012;66:755-757.
28. Caudle WM, Richardson JR, Wang MZ, et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007;27:8138-8148.
29. Taylor TN, Caudle WM, Miller GW. VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis 2011;2011:124165.
30. Kurian MA, Zhen J, Cheng SY, et al. Homozygous loss-offunction mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 2009;119:1595-1603.
31. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 2011;33:195-201.
32. Stamelou M, Mencacci NE, Cordivari C, et al. Myoclonusdystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 2012;79:435-441.
33. Robertson D, Flattem N, Tellioglu T, et al. Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann NY Acad Sci 2001;940:527-543.
34. Garland EM, Hahn MK, Ketch TP, et al. Genetic basis of clinical catecholamine disorders. Ann NY Acad Sci 2002; 971:506-514.
35. Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamineserotonin vesicular transport disease and its treatment. N Engl J Med 2013;368:543-550.
36. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-1212.
37. Martin WR, Wieler M, Stoessl AJ, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 2008;63:388-394.
38. Okamura N, Villemagne VL, Drago J, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 2010;51:223-228.
39. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 2006;15:299-305.
40. Brighina L, Riva C, Bertola F, et al. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. Neurobiol Aging 2013;34:1712.e9-1712.e13.
41. Lev N, Barhum Y, Pilosof NS, et al. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging. J Gerontol A Biol Sci Med Sci 2013;68:215-225.
42. Mazei-Robison MS, Bowton E, Holy M, et al. Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci 2008;28:7040-7046.
43. Lesch KP, Bengel D, Heils A, et al. Association of anxietyrelated traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
44. Clarke H, Flint J, Attwood AS, Munafo MR. Association of the 5-HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med 2010;40:1767-1778.
45. Kiyohara C, Yoshimasu K. Association between major depressive disorder and a functional polymorphism of the 5-hydroxytryptamine (serotonin) transporter gene: a meta-analysis. Psychiatr Genet 2010;20:49-58.
46. Lasky-Su JA, Faraone SV, Glatt SJ, TsuangMT. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 2005;133B:110-115.
47. Huang CH, Santangelo SL. Autism and serotonin transporter gene polymorphisms: a systematic review and metaanalysis. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:903-913.
48. Lin PY. Meta-analysis of the association of serotonin transporter gene polymorphism with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:683-689.
49. Calati R, De Ronchi D, Bellini M, Serretti A. The 5-HTTLPR polymorphism and eating disorders: a metaanalysis. Int J Eat Disord 2011;44:191-199.
50. Haenisch B, Herms S, Mattheisen M, et al. Genome-wide association data provide further support for an association between 5-HTTLPR and major depressive disorder. J Affect Disord 2013;146:438-440.
51. Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD. Enhanced activity of human serotonin transporter variants associated with autism. Philos Trans R Soc Lond B Biol Sci 2009; 364:163-173.
52. Haenisch B, Linsel K, Bruss M, et al. Association of major depression with rare functional variants in norepinephrine transporter and serotonin1A receptor genes. Am J Med Genet B Neuropsychiatr Genet 2009;150B:1013-1016.
53. Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 2011;69:628-649.
54. Lohoff FW, Hodge R, Narasimhan S, et al. Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry Epub 2013 Jan
55. Baudry A, Mouillet-Richard S, Launay JM, Kellermann O. New views on antidepressant action. Curr Opin Neurobiol 2011;21:858-865.
56. Perona MT, Waters S, Hall FS, et al. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 2008;19:566-574.
57. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci 2010;13:1161-1169.
58. Haenisch B, Bonisch H. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 2011; 129:352-368.
59. Mariotti KC, Rossato LG, Froehlich PE, Limberger RP. Amphetamine-type medicines: a review of pharmacokinetics, pharmacodynamics, and toxicological aspects. Curr Clin Pharmacol Epub 2013 Jan
60. Robertson SD, Matthies HJ, Galli A. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 2009;39:73-80.